Deferred Tax Assets, Valuation Allowance of Grace Therapeutics, Inc. from 31 Mar 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Grace Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Mar 2019 to 31 Mar 2025.
  • Grace Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Mar 2025 was $49,530,000, a 4.8% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Grace Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $49,530,000 +$2,246,000 +4.8% 31 Mar 2025 10-K 23 Jun 2025 2025 FY
Q1 2024 $47,284,000 +$620,000 +1.3% 31 Mar 2024 10-K 23 Jun 2025 2025 FY
Q1 2023 $46,664,000 +$4,263,000 +10% 31 Mar 2023 10-K 21 Jun 2024 2024 FY
Q1 2022 $42,401,000 +$3,070,000 +7.8% 31 Mar 2022 10-K 23 Jun 2023 2023 FY
Q1 2021 $39,331,000 +$8,868,000 +29% 31 Mar 2021 10-K 21 Jun 2022 2022 FY
Q1 2020 $30,463,000 +$4,501,000 +17% 31 Mar 2020 10-K 22 Jun 2021 2021 FY
Q1 2019 $25,962,000 31 Mar 2019 10-K 29 Jun 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.